Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 64 of 71 for:    TELMISARTAN AND HYDROCHLOROTHIAZIDE

Relative Bioavailability of Telmisartan and HCTZ in Two Experimental Formulations Compared to the Standard Formulation Telmisartan and HCTZ in Healthy Female and Male Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02262572
Recruitment Status : Completed
First Posted : October 13, 2014
Last Update Posted : October 13, 2014
Sponsor:
Information provided by (Responsible Party):
Boehringer Ingelheim

Brief Summary:
Study to assess the comparative pharmacokinetics of telmisartan/HCTZ in two new formulations based on sodium salt compared to the present commercial formulation (MicardisPlus®)

Condition or disease Intervention/treatment Phase
Healthy Drug: Telmisartan /HCTZ - compression tablet (DC) Drug: Telmisartan /HCTZ - dry granulation tablet (DG) Drug: Telmisartan /HCTZ - present commercial formulation Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 24 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Relative Bioavailability of Telmisartan and HCTZ p.o. (80 mg Telmisartan/12.5 mg HCTZ) in Two Experimental Formulations (Given t.i.d. for One Day Each) Compared to the Standard Formulation 80 mg Telmisartan/12.5 mg HCTZ (MicardisPlus®), Given t.i.d. for One Day in Healthy Female and Male Subjects. A Three-way Crossover, Open, Randomised Study
Study Start Date : April 2003
Actual Primary Completion Date : August 2003

Resource links provided by the National Library of Medicine

Drug Information available for: Telmisartan

Arm Intervention/treatment
Experimental: Telmisartan /HCTZ - compression tablet (DC) Drug: Telmisartan /HCTZ - compression tablet (DC)
Experimental: Telmisartan /HCTZ - dry granulation tablet (DG) Drug: Telmisartan /HCTZ - dry granulation tablet (DG)
Active Comparator: Telmisartan /HCTZ - present commercial formulation Drug: Telmisartan /HCTZ - present commercial formulation
Other Name: MicardisPlus®




Primary Outcome Measures :
  1. AUC0-∞ (Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity) [ Time Frame: up to 72 hours after drug administration ]
  2. Cmax (Maximum measured concentration of the analyte in plasma) [ Time Frame: up to 72 hours after drug administration ]
  3. Amount of HCTZ excreted in urine over 48 hours (%Ae0-48h) [ Time Frame: up to 48 hours after drug administration ]

Secondary Outcome Measures :
  1. tmax (Time from dosing to the maximum concentration of the analyte in plasma) [ Time Frame: up to 72 hours after drug administration ]
  2. t1/2 (Terminal half-life of the analyte in plasma) [ Time Frame: up to 72 hours after drug administration ]
  3. CLtot/F (Apparent clearance of the analyte in plasma following extravascular administration) [ Time Frame: up to 72 hours after drug administration ]
  4. MRTtot (Total mean residence time) [ Time Frame: up to 72 hours after drug administration ]
  5. Vz/F (Apparent volume of distribution during the terminal phase λz following an extravascular dose) [ Time Frame: up to 72 hours after drug administration ]
  6. Number of subjects with adverse events [ Time Frame: up to 32 days ]
  7. Number of subjects with clinically significant findings in vital signs [ Time Frame: up to 32 days ]
    blood pressure, pulse rate

  8. Number of subjects with clinically significant findings in 12 lead ECG [ Time Frame: up to 32 days ]
  9. Investigator's assessment of tolerability on a 4-point scale [ Time Frame: up to 32 days ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

Subjects meeting the following criteria will be eligible for participation in the study:

  • Healthy male and female subjects according to the following criteria: based upon a complete medical history, including the physical examination, vital signs (BP, HR), 12-lead ECG, clinical laboratory tests.
  • Laboratory values within a clinically defined reference range
  • Signed and dated written informed consent prior to admission to the study in accordance with Good Clinical Practice (GCP) and local legislation
  • Age >=18 and Age <=55 years
  • Body mass index (BMI) >=18.5 and <=29.9 kg/m2
  • Able to communicate well with the investigator and to comply with study requirements
  • Good condition of veins

Exclusion Criteria:

  • Any finding of the medical examination (including blood pressure, heart rate, and electrocardiogram) deviating from normal and of clinical relevance
  • Supine blood pressure at screening of systolic ≤ 110 mm Hg and diastolic ≤ 60 mmHg
  • Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunologic or hormonal disorders
  • Surgery of gastrointestinal tract (except appendectomy)
  • Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
  • History of relevant orthostatic hypotension, fainting spells or blackouts
  • Chronic or relevant acute infections
  • History of an allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator
  • Intake of drugs with a long half-life (> 24 hours) within at least one month or less than 10 half-lives of the respective drug prior to administration or during the trial
  • Use of any drugs, which might reasonably influence the results of the trial based on the knowledge at the time of protocol preparation within 10 days prior to administration or during the trial
  • Participation in another trial with an investigational drug within two months prior to administration or during the trial
  • Smoker (more than 10 cigarettes or three cigars or three pipes/day)
  • Alcohol abuse (more than 60 g/day)
  • Drug abuse
  • Blood donation or loss of more than 400 mL within four weeks prior to administration or during the trial
  • Excessive physical activities (within five days prior to administration or during the trial)
  • Any laboratory value outside the reference range of clinical relevance
  • History of hereditary fructose intolerance
  • Veins unsuited for i.v. puncture on either arm (e.g. veins which are difficult to locate, access or puncture, veins with a tendency to rupture during or after puncture, etc.)
  • Inability to comply with the dietary regimen of study centre
  • Inability to comply with the investigator's instructions.

For female subjects:

  • Pregnancy
  • Positive pregnancy test
  • No adequate contraception e.g. oral contraceptives, sterilization, intrauterine device (IUD)
  • Inability to maintain this adequate contraception during the whole study period
  • Lactation period

Additional Information:
Layout table for additonal information
Responsible Party: Boehringer Ingelheim
ClinicalTrials.gov Identifier: NCT02262572     History of Changes
Other Study ID Numbers: 502.415
First Posted: October 13, 2014    Key Record Dates
Last Update Posted: October 13, 2014
Last Verified: October 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Telmisartan
Hydrochlorothiazide
Telmisartan, hydrochlorothiazide drug combination
Antihypertensive Agents
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists
Molecular Mechanisms of Pharmacological Action
Diuretics
Natriuretic Agents
Physiological Effects of Drugs
Sodium Chloride Symporter Inhibitors
Membrane Transport Modulators